Loading organizations...
CorVent Medical develops respiratory care solutions, featuring its RESPOND® Ventilator. This medical device provides simple, safe, and smart ventilation for emergency and daily use in healthcare settings. It offers invasive and non-invasive capabilities, including auto-leak compensation, designed to streamline patient care and reduce operational complexity.
Founded around 2020 by figures including CEO Richard S. Walsh, CorVent Medical originated from the insight to simplify complex medical technology. This was reportedly driven by a global demand for accessible respiratory devices during a health crisis. Walsh's extensive medical device experience guided the creation of these intuitive solutions.
CorVent Medical's products serve healthcare providers, from general hospitals to rural clinics. Its mission is to improve patient outcomes and expand access to quality respiratory care through value-based breathing technologies. The company aims to reduce complexity for providers and patients, ensuring essential treatment tools are readily available.
CorVent Medical has raised $5.0M across 1 funding round.
CorVent Medical has raised $5.0M in total across 1 funding round.
# CorVent Medical: Transforming Critical Care Through AI-Driven Respiratory Innovation
CorVent Medical is a U.S.-based medical device company specializing in respiratory care technology, founded in 2020 to address critical gaps in ventilation accessibility and affordability.[1][2] The company develops and manufactures the RESPOND® Ventilator—a simple, safe, and smart medical device designed for hospitals, critical access hospitals, long-term care facilities, and skilled nursing facilities.[5] Beyond hardware, CorVent is expanding into AI/ML-driven digital solutions through its CorVision™ SaaS platform, which integrates with hospital EMR systems and telemedicine networks to optimize ventilator management and critical care decision-making.[1]
CorVent serves healthcare systems facing unprecedented clinical complexity, staffing shortages, and rising patient acuity—particularly in rural and resource-limited environments.[1] The company has achieved significant commercial traction, raising over $45 million in Series A funding and now pursuing Series B financing to scale its digital respiratory care portfolio.[1] With headquarters and manufacturing operations in Fargo, North Dakota, CorVent combines clinical expertise with technology innovation to improve outcomes for critically ill patients across both urban and rural settings.[2][5]
CorVent Medical was established in 2020 in direct response to the COVID-19 pandemic, with a founding vision to revolutionize respiratory support by developing versatile, high-performance ventilators.[2] The company quickly gained recognition, becoming a top 5 finalist among 172 entries in the U.S. Department of Defense Hack-a-Vent Challenge and securing FDA Emergency Use Authorization (EUA) for the RESPOND-19 Ventilator.[2]
The company's trajectory reflects both clinical need and regulatory validation. CorVent relocated and expanded its U.S. headquarters to Fargo, North Dakota, building a team of industry leaders committed to excellence.[2] A pivotal milestone came with FDA 510(k) clearance and commercial launch of the RESPOND® Ventilator, establishing the company as a credible player in critical care technology.[2] This foundation of regulatory success and clinical credibility positioned CorVent for its current expansion into AI/ML-driven platforms, with plans to submit a 510(k) application for CorVision™ in November 2025.[1]
CorVent operates at the intersection of three significant healthcare trends: critical care workforce shortages, rural healthcare access gaps, and the digitalization of medical devices.[1] The timing is particularly acute—hospitals face unprecedented staffing challenges and rising patient acuity, creating urgent demand for both reliable hardware and intelligent decision-support software.[1]
The company's expansion into AI/ML-driven platforms reflects a broader industry shift toward predictive analytics and remote monitoring in critical care. By integrating hardware and software, CorVent positions itself to strengthen healthcare system resilience—a priority that gained prominence during the pandemic and remains central to hospital infrastructure planning.[1] The company's focus on rural and resource-limited environments also addresses a structural gap in the healthcare ecosystem, where access to advanced respiratory care has historically been constrained by cost and complexity.[1]
CorVent's investor relations strategy—including attendance at the J.P. Morgan Healthcare Conference in January 2026—signals confidence in the broader medtech investment landscape and suggests the company is positioned to influence how critical care technology is funded and deployed.[1]
CorVent Medical is executing a hardware-to-platform transition that mirrors successful patterns in medtech: establish credibility and market presence with a differentiated physical product, then layer software and AI capabilities to create recurring revenue and deeper clinical integration.[1] The company's Series B financing and planned CorVision™ FDA submission indicate aggressive scaling ambitions.
The next phase will likely determine whether CorVent can achieve meaningful adoption of its SaaS platform across hospital networks—a challenge that requires not just technical excellence but also clinical validation, integration partnerships, and reimbursement pathways. Success would position the company as a critical infrastructure provider for intensive care units, particularly in underserved markets. The company's commitment to U.S. manufacturing and rural healthcare access also aligns with broader policy tailwinds around healthcare supply chain resilience and rural health investment, potentially creating favorable conditions for growth and partnership opportunities.
CorVent Medical has raised $5.0M in total across 1 funding round.
CorVent Medical's investors include Soffinova Partners, Paul Walker, Jim Swartz, Exor Ventures, Genesis MedTech Group, Redmile Group, The Deerfield Foundation, The Pagliuca Family Office.
CorVent Medical has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in May 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2020 | $5.0M Seed | Soffinova Partners | Paul Walker, Jim Swartz, Exor Ventures, Genesis MedTech Group, Redmile Group, The Deerfield Foundation, The Pagliuca Family Office |